Santhera announces the signing of an exclusive agreement with Biomedica for the distribution of AGAMREE (vamorolone) in Russia, for the treatment of Duchenne muscular dystrophy (DMD) in patients four years of age and older.
Under the terms of the agreement, Santhera will receive a percentage of net sales, in line with previous distribution agreements, with sales expected to begin in Q1 2026. This collaboration will enable access to AGAMREE for DMD patients across the country, facilitated through regional and national managed access programs. There are approximately 1,400 patients living with DMD in Russia. (What is Agamree (vamorolone)? What is Agamree Used For?)
Dario Eklund, Chief Executive Officer of Santhera, said: “This agreement will enable more children to access this important DMD treatment, and is the latest in a series of global agreements secured in 2025. We look forward to working closely with Biomedica in the months ahead.”
Oleg Parosin, Founder and Chief Executive Officer of Biomedica added: “Our deep expertise in neurology and DMD, particularly with therapies that complement AGAMREE, combined with our track record of successful partnerships with leading EU and US companies, positions us as a strong and trusted partner for Santhera in Russia. We look forward to working together to accelerate access and ensure the availability of AGAMREE from early next year, enabling even more patients to benefit from this essential therapy.”
